Michael House

Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…

Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…

BACKGROUND: Accurate clinical staging plays a key role in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC)…

BACKGROUND: Historical pediatric data recommend surgical resection for type I choledochal cysts due to the risk of malignant progression over time up to 30%…

Laparoscopic subtotal cholecystectomy (STC) is an established approach for difficult cholecystectomy (CCY) and is endorsed by guidelines as a strategy to mitigate risk for complications such as bile duct injury…

Patients with chronic pancreatitis (CP) predominantly involving the pancreatic body/tail benefit from distal pancreatectomy (DP), with most experiencing long-term improvements in symptoms after recovery from surgery…

Goblet cell adenocarcinoma is a rare malignancy with an incidence of 1 per 2 million people worldwide…

Splenectomy carries risk of infectious complications. Splenic preservation (SP) avoids these immunologic consequences but is not common surgical practice. When permissible by clinical status and pathology, SP may be acceptable in select patients…